INmune Bio
INMB
28 hedge funds and large institutions have $10.3M invested in INmune Bio in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 4 closing their positions.
445% more capital invested
Capital invested by funds: $1.88M → $10.3M (+$8.37M)
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
75% more funds holding
Funds holding: 16 → 28 (+12)
4.07% more ownership
Funds ownership: 3.32% → 7.38% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$2.54M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.02M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$750K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$623K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$2.22M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7.68K |
| 3 |
BlackRock
New York
|
-$4.2K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PFS
26
Prospera Financial Services
Dallas,
Texas
| $2K | +$1.78K | +175 | New |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$31 | +3 | +3% |
|
|
28
UBS Group
Zurich,
Switzerland
| – | -$4K | -820 | Closed |
|
|
PAG
29
Private Advisor Group
Morristown,
New Jersey
| – | -$4K | -675 | Closed |
|
30
Wells Fargo
San Francisco,
California
| – | +$173 | +17 | +74% |
|
INMB Hedge Fund Activity: Q3 2020 in Review
28 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q3 2020, worth a combined $10.3M — up 445% from $1.88M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new INMB positions and 4 closed out — a net gain of 12 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Granite Point Capital Management, opening a new position worth an estimated $2.54M. The largest seller was Financial Advocates Investment Management, cutting an estimated $2.22M.
- 28 institutional investors held INmune Bio (INMB) as of Q3 2020, up from 16 in Q2 2020.
- Funds reported $10.3M of INmune Bio stock for Q3 2020, up 445% quarter-over-quarter.
- 16 funds opened new INmune Bio positions in Q3 2020 and 4 closed out, a net change of +12 holders.
- The largest INmune Bio buyer in Q3 2020 was Granite Point Capital Management, an estimated $2.54M added.
- The largest INmune Bio seller in Q3 2020 was Financial Advocates Investment Management, an estimated $2.22M sold.
Based on aggregated 13F filings for Q3 2020.